WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

DDD alterations from 2005-2024

Cumulative overview of all DDD alterations performed in the period 2005-2024. The year changed is when the alterations were implemented in the ATC/DDD Index. Please note that a DDD may have changed more than once for some ATC codes. The ATC codes are current codes. For substances where the DDD is changed twice the new DDD which is not according to current value is marked with an asterix (*).

List of abbrevations

SubstancePrevious DDDNew DDD*Present ATC codeYear changed
vasopressin (argipressin)4UP40UPH01BA012019
tiotropium bromide18mcg 4)Inhal. powder10mcg 4)Inhal. powderR03BB042017
thioctic acid0.2gO,P0.6gO,PA16AX012017
temocillin2gP4gPJ01CA172019
sodium selenite0.2mgPdeleted 6)A12CE022023
sirolimus6mgO3mgOL04AA102006
simvastatin15mgO30mgOC10AA012009
rivaroxaban10mgO20mgOB01AF012016
risperidone1.8mgP depot2.7mgP depotN05AX082010
pravastatin20mgO30mgOC10AA032009
posaconazole0.8gO0.3gOJ02AC042017
mifepristone0.6 gO0.2gOG03XB012017
meropenem2gP3gPJ01DH022019
magnesium sulfate1gPdeleted 6)A12CC022023
magnesium chloride0.8gPdeleted 6)A12CC012023
lovastatin30mgO45mgOC10AA022009
liraglutide1.2mgP1.5mgPA10BJ022020
levetiracetam2gO1.5gON03AX142005
ibrandronic acid5mgP6mgPM05BA062007
human menopausal gonadotrophin30UP75UPG03GA022016
glycopyrronium bromide3mgP0.3mgPA03AB022018
gliclazide0.16gO60mgOA10BB092011
fluvastatin40mgO60mgOC10AA042009
fentanyl0.6mgTD1.2mgTDN02AB032005
esomeprazole20mgO30mgOA02BC052005
desmopressin0.36mg 1)SL0.24mg 1)SLH01BA022009
daclizumab0.35gP5mgPL04AC012018
dabigatran etexilate 0.22gO0.3gOB01AE072016
colistin3MUP9MUPJ01XB012019
ciprofloxacin0.5gP0.8gPJ01MA022019
ceftezole6gP3gPJ01DB122008
cefepime2gP4gPJ01DE012019
calcium laevulate1gPdeleted 6)A12AA302023
calcium gluconate3gPdeleted 6)A12AA032023
calcium glubionate 2.75gPdeleted 6)A12AA022023
calcium chloride0.2gPdeleted 6)A12AA072023
calcium acetate2gO6gOV03AE072017
budesonide2mgSL1.5mgSLA07EA062024
blood coagulation factors1deleted 2)B02BD2017
baricitinib4mgO3mgOL04AA372023
atorvastatin10mgO20mgOC10AA052009
aprepitant95mgO165mgOA04AD122019
aprepitant 5)95mgP150mgPA04AD122019
apixaban5mgO10mgOB01AF022016
amprenavir2.4gO1.2gOJ05AE052006
ampicillin2gP6gPJ01CA012019
ampicillin and enzyme inhibitor23)P63)PJ01CR012017
amoxicillin1gP3gPJ01CA042019
amoxicillin1gO1.5gOJ01CA042019
amoxicillin and enzyme inhibitor1gP3gPJ01CR022005
amoxicillin and beta-lactamase inhibitor1gO1.5gOJ01CR022019
alosetron2mgO1mgOA03AE012005
1) Base.
2) DDDs for the various blood coagulation factors in all ATC 5th level codes in B02BD are deleted. No new DDDs will be established in B02BD Blood coagulation factors.
3) Refers to ampicillin.
4) The DDD for tiotropium bromide is unchanged but has been defined as the content of one inhalation capsule (18 mcg) as tiotropium. Since there are different inhalation capsules on the market containing different amounts of active substance, the DDD is now defined as the delivered dose, which is the same (10 mcg) as tiotropium for all products.
5) Refers to fosaprepitant
6) Parenteral DDDs in A12 are deleted. All parenteral solutions of electrolytes should be classified in B05B or in B05X.

Last updated: 2023-12-15